Evidence map›Paper›PMID 31501790›Full record

ArticleClinical and experimental hepatology2019

Soluble CD25 as a predictor of hepatocellular carcinoma compared with alpha-fetoprotein.

Shaymaa Nafady Abdelfattah, Alaa Farouk Haseeb, Mohammad Mohammad Tawfik, Doaa Mahmoud Khalil, Dina Attia

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and experimental hepatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 4 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Shaymaa Nafady AbdelfattahDepartment of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Alaa Farouk HaseebDepartment of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Mohammad Mohammad TawfikDepartment of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Doaa Mahmoud KhalilPublic Health and Community Medicine Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Dina AttiaDepartment of Gastroenterology, Hepatology and Endemic Medicine, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt.
Beni-Suef University · EG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

aim of the studyWe aimed to evaluate soluble CD25 (sCD25) as a marker for hepatocellular carcinoma (HCC) diagnosis. MATERIAL AND

methodsEighty-eight subjects were enrolled in our study in the years 2017-2018. They were divided into three groups as follows: group 1 - HCC group (

resultsThe levels of sCD25 and AFP were higher in HCC patients than cirrhotic and control groups without a statistically significant difference between the three groups (

conclusionssCD25 seems to offer no better detection rate of HCC compared to AFP with lower sensitivity and specificity.

Indexed as

alpha-fetoproteinHCC markershepatocellular carcinomasoluble CD25

Identifiers

PMID31501790
PMCPMC6728866
OpenAlexW2947902307

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-SA
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.